Nektar Therapeutics Shares Outstanding 2006-2019 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 175
Q2 2019 175
Q1 2019 174
Q4 2018 180
Q3 2018 173
Q2 2018 182
Q1 2018 161
Q4 2017 156
Q3 2017 163
Q2 2017 155
Q1 2017 154
Q4 2016 140
Q3 2016 137
Q2 2016 136
Q1 2016 136
Q4 2015 132
Q3 2015 133
Q2 2015 132
Q1 2015 136
Q4 2014 127
Q3 2014 132
Q2 2014 127
Q1 2014 124
Q4 2013 116
Q3 2013 116
Q2 2013 116
Q1 2013 115
Q4 2012 115
Q3 2012 115
Q2 2012 115
Q1 2012 115
Q4 2011 113
Q3 2011 114
Q2 2011 114
Q1 2011 109
Q4 2010 94
Q3 2010 94
Q2 2010 94
Q1 2010 94
Q4 2009 93
Q3 2009 93
Q2 2009 93
Q1 2009 93
Q4 2008 92
Q3 2008 92
Q2 2008 92
Q1 2008 92
Q4 2007 92
Q3 2007 92
Q2 2007 92
Q1 2007 91
Q4 2006 90
Q3 2006 90
Q2 2006 90
Q1 2006 89
Q4 2005 86
Q3 2005 86
Q2 2005 85
Q1 2005 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.139B $1.193B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $67.550B 39.07
Takeda Pharmaceutical (TAK) Japan $58.571B 10.38
Astellas Pharma (ALPMY) Japan $32.091B 16.03
Eisai (ESALY) Japan $22.967B 44.28
UCB SA (UCBJF) Belgium $18.867B 0.00
Grifols, S.A (GRFS) Spain $17.622B 23.09
Merck (MKGAF) Germany $17.318B 23.63
Neurocrine Biosciences (NBIX) United States $9.609B 266.97
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.636B 35.53
Ionis Pharmaceuticals (IONS) United States $8.509B 17.23
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.627B 9.74
IPSEN SA ADR (IPSEY) France $6.090B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.877B 0.00
Orion OYJ (ORINY) Finland $5.871B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hypermarcas (HYPMY) Brazil $5.178B 15.75
United Therapeutics (UTHR) United States $4.694B 0.00
Evotec AG (EVTCY) Germany $4.138B 66.78
FibroGen (FGEN) United States $3.968B 116.61
Arrowhead Pharmaceuticals (ARWR) United States $3.913B 72.62
Sage Therapeutics (SAGE) United States $3.603B 0.00
PTC Therapeutics (PTCT) United States $3.524B 0.00
ChemoCentryx (CCXI) United States $2.837B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.802B 11.34
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.277B 0.00
Pacira Pharmaceuticals (PCRX) United States $2.024B 55.74
Xencor (XNCR) United States $1.995B 60.64
Tilray (TLRY) Canada $1.947B 0.00
Heron Therapeutics (HRTX) United States $1.932B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.840B 22.36
Corcept Therapeutics (CORT) United States $1.553B 17.42
USANA Health Sciences (USNA) United States $1.525B 15.94
Theravance Biopharma (TBPH) Cayman Islands $1.463B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.392B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.391B 9.49
Endo (ENDP) Ireland $1.377B 2.53
Zogenix (ZGNX) United States $1.335B 0.00
Akebia Therapeutics (AKBA) United States $1.207B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.060B 32.84
Portola Pharmaceuticals (PTLA) United States $1.051B 0.00
Karyopharm Therapeutics (KPTI) United States $1.010B 0.00
Aerie Pharmaceuticals (AERI) United States $1.000B 0.00
Radius Health (RDUS) United States $0.894B 0.00
ImmunoGen (IMGN) United States $0.810B 0.00
Collegium Pharmaceutical (COLL) United States $0.802B 0.00
Flexion Therapeutics (FLXN) United States $0.661B 0.00
Molecular Templates (MTEM) United States $0.659B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.571B 0.00
TherapeuticsMD (TXMD) United States $0.559B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.537B 65.13
Ardelyx (ARDX) United States $0.528B 0.00
Translate Bio (TBIO) United States $0.474B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.470B 20.27
Organogenesis Holdings (ORGO) United States $0.458B 0.00
Innate Pharma SA (IPHYF) France $0.446B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.419B 0.00
DURECT (DRRX) United States $0.417B 0.00
Calithera Biosciences (CALA) United States $0.402B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.386B 0.00
Recro Pharma (REPH) United States $0.384B 0.00
Siga Technologies (SIGA) United States $0.383B 8.76
BioCryst Pharmaceuticals (BCRX) United States $0.378B 0.00
Harpoon Therapeutics (HARP) United States $0.377B 0.00
Lannett Co Inc (LCI) United States $0.369B 5.94
Indivior (INVVY) United States $0.356B 2.11
Corbus Pharmaceuticals Holdings (CRBP) United States $0.355B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.352B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.343B 0.00
Rafael Holdings (RFL) United States $0.333B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.330B 0.00
Concert Pharmaceuticals (CNCE) United States $0.327B 0.00
OptiNose (OPTN) United States $0.310B 0.00
Ocular Therapeutix (OCUL) United States $0.272B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.269B 0.00
MEI Pharma (MEIP) United States $0.251B 0.00
KalVista Pharmaceuticals (KALV) United States $0.249B 0.00
IMV INC (IMV) Canada $0.238B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.221B 0.00
Nature's Sunshine Products (NATR) United States $0.199B 34.30
Taiwan Liposome (TLC) Taiwan $0.195B 0.00
Jounce Therapeutics (JNCE) United States $0.175B 2.35
Galmed Pharmaceuticals (GLMD) Israel $0.130B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.125B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.123B 0.00
Xeris Pharmaceuticals (XERS) United States $0.118B 0.00
CannTrust Holdings (CTST) Canada $0.117B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.114B 0.00
Otonomy (OTIC) United States $0.109B 0.00
Redhill Biopharma (RDHL) Israel $0.107B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.106B 0.00
Aquestive Therapeutics (AQST) United States $0.106B 0.00
CV Sciences (CVSI) United States $0.087B 0.00
Infinity Pharmaceuticals (INFI) United States $0.083B 0.00
Neos Therapeutics (NEOS) United States $0.082B 0.00
Champions Oncology (CSBR) United States $0.081B 0.00
MediWound (MDWD) Israel $0.081B 0.00
Onconova Therapeutics (ONTX) United States $0.074B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.068B 20.45
Entasis Therapeutics Holdings (ETTX) United States $0.068B 0.00
CTI BioPharma (CTIC) United States $0.068B 0.00
SCYNEXIS (SCYX) United States $0.064B 0.00
Nivalis Therapeutics (ALPN) United States $0.060B 0.00
Aclaris Therapeutics (ACRS) United States $0.060B 0.00
RENEURON GP (RNUGF) United Kingdom $0.059B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.053B 0.00
VAXART, INC (VXRT) United States $0.052B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.051B 23.03
Forward Pharma (FWP) Denmark $0.049B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.047B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
PolarityTE (PTE) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.042B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.039B 0.00
Mannatechorporated (MTEX) United States $0.037B 0.00
Jaguar Animal Health (JAGX) United States $0.036B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.029B 0.00
Vical (BBI) United States $0.027B 0.00
Biomerica (BMRA) United States $0.027B 0.00
PharmAthene (ALT) United States $0.027B 0.00
China SXT Pharmaceuticals (SXTC) China $0.026B 0.00
ProPhase Labs (PRPH) United States $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Regulus Therapeutics (RGLS) United States $0.017B 0.00
Cardiome Pharma (CORV) Canada $0.016B 0.00
Shineco (TYHT) China $0.016B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Novan (NOVN) United States $0.015B 0.00
HANCOCK JAFFE (HJLI) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
Lipocine (LPCN) United States $0.012B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00